Decision criteria for resource allocation: an analysis of CONITEC oncology reports

Abstract

In health technology assessment (HTA), decision criteria are considered relevant to support the complex deliberative process that requires simultaneous consideration of multiple factors. The aim was to identify and analyze the decision criteria that have been used by the National Health Technology Assessment Commission (CONITEC) when recommending the incorporation of technologies for the treatment of cancer. Descriptive study, based on reports from CONITEC, between 2012 and 2018, on oncology technologies. The data were collected in a specific extraction form and analyzed using descriptive statistics. 39 reports were analyzed, 15 of them did not present any explicit decision criteria. Medicines were the most frequently evaluated type of technology. The most frequent types of cancers were: breast cancer, head and neck cancer, colorectal cancer, non-Hodgkin’s lymphoma and lung cancer. The most frequently considered criteria were: financial impact and effectiveness. The study identified the decision criteria that have been most used in the area of oncology, however, the lack of transparency in relation to the weight of these criteria makes it difficult to understand their influence on the result of the decisions taken.

Treatment patterns and healthcare resource utilization for triple negative breast cancer in the Brazilian private healthcare system: a database study

“…Additionally, in 2022 were also approved antibody–drug conjugates trastuzumab deruxtecan for HER2-low 44 and the sacituzumab govitecan 45 , both in latter lines of metastatic TNBC. Nonetheless, the scenario depicted in this study still represents the reality of public health sector in Brazil where none of these technologies were incorporated since their approvals, as it requires health technology assessment by CONITEC, a committee from the Ministry of Health 46 . Due to this anachronical timeframes, it is expected that a new study assessing the current private health sector treatment patterns and HCRU may result in a different portrait, with higher HCRU in both early and advanced stages of TNBC.…”